<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339998</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Endurance Exercise Does Not Exacerbate Cardiac Inflammation in BALB/c Mice Following mRNA COVID-19 Vaccination.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">966</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090966</ELocationID><Abstract><AbstractText>The mechanism underlying myopericarditis associated with mRNA COVID-19 vaccination, including increased susceptibility in young males, remains poorly understood. This study aims to explore the hypothesis that engaging in physical exercise at the time of mRNA COVID-19 vaccination may promote a cardiac inflammatory response, leading to the development of myopericarditis. Male BALB/c mice underwent treadmill running or remained sedentary for five weeks. Subsequently, two doses of the Pfizer/BioNTech vaccine or vehicle were administered with a 14-day interval, while the exercise regimen continued. The animals were euthanized days after the second vaccination. Vaccination was followed by body weight loss, increased hepatic inflammation, and an antigen-specific T cell response. Small foci of fibrovascular inflammation and focal cell loss were observed in the right ventricle, irrespective of vaccination and/or exercise. Vaccination did not elevate cardiac troponin levels. Cardiac tissue from the vaccinated mice showed upregulated mRNA expression of the genes IFNγ and IL-1β, but not IL-6 or TNFα. This pro-inflammatory signature in the heart was not exacerbated by endurance exercise. Ex vivo vascular reactivity remained unaffected by vaccination. Our data provide evidence for the cardiac safety of mRNA COVID-19 vaccination. The role of exercise in the development of pro-inflammatory cardiac changes post mRNA vaccination could not be established.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eens</LastName><ForeName>Sander</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Group Cardiovascular Diseases, GENCOR, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Physiopharmacology, GENCOR, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hecke</LastName><ForeName>Manon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Translational Cell and Tissue Research, Department of Imaging and Pathology, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Bogaert</LastName><ForeName>Siel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Physiopharmacology, GENCOR, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Favere</LastName><ForeName>Kasper</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Research Group Cardiovascular Diseases, GENCOR, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Physiopharmacology, GENCOR, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Antwerp University Hospital, 2650 Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cools</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0459-901X</Identifier><AffiliationInfo><Affiliation>Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fransen</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre of Medical Genetics, University of Antwerp and Antwerp University Hospital, 2650 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roskams</LastName><ForeName>Tania</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2816-1530</Identifier><AffiliationInfo><Affiliation>Laboratory of Translational Cell and Tissue Research, Department of Imaging and Pathology, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidbuchel</LastName><ForeName>Hein</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9301-8127</Identifier><AffiliationInfo><Affiliation>Research Group Cardiovascular Diseases, GENCOR, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Antwerp University Hospital, 2650 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guns</LastName><ForeName>Pieter-Jan</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8640-6620</Identifier><AffiliationInfo><Affiliation>Laboratory of Physiopharmacology, GENCOR, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">endurance exercise</Keyword><Keyword MajorTopicYN="N">exercise</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword><Keyword MajorTopicYN="N">myopericarditis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339998</ArticleId><ArticleId IdType="pmc">PMC11435831</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090966</ArticleId><ArticleId IdType="pii">vaccines12090966</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grana C., Ghosn L., Evrenoglou T., Jarde A., Minozzi S., Bergman H., Buckley B.S., Probyn K., Villanueva G., Henschke N., et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev. 2022;12:CD015477. doi: 10.1002/14651858.CD015477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD015477</ArticleId><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E., Ritchie H., Ortiz-Ospina E., Roser M., Hasell J., Appel C., Giattino C., Rodes-Guirao L. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 2021;5:947–953. doi: 10.1038/s41562-021-01122-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41562-021-01122-8</ArticleId><ArticleId IdType="pubmed">33972767</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein N.P., Lewis N., Goddard K., Fireman B., Zerbo O., Hanson K.E., Donahue J.G., Kharbanda E.O., Naleway A., Nelson J.C., et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326:1390–1399. doi: 10.1001/jama.2021.15072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15072</ArticleId><ArticleId IdType="pmc">PMC8511971</ArticleId><ArticleId IdType="pubmed">34477808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144:471–484. doi: 10.1161/CIRCULATIONAHA.121.056135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId><ArticleId IdType="pmc">PMC8340726</ArticleId><ArticleId IdType="pubmed">34281357</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymans S., Cooper L.T. Myocarditis after COVID-19 mRNA vaccination: Clinical observations and potential mechanisms. Nat. Rev. Cardiol. 2022;19:75–77. doi: 10.1038/s41569-021-00662-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00662-w</ArticleId><ArticleId IdType="pmc">PMC8656440</ArticleId><ArticleId IdType="pubmed">34887571</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasmin F., Najeeb H., Naeem U., Moeed A., Atif A.R., Asghar M.S., Nimri N., Saleem M., Bandyopadhyay D., Krittanawong C., et al. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun. Inflamm. Dis. 2023;11:e807. doi: 10.1002/iid3.807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.807</ArticleId><ArticleId IdType="pmc">PMC10022421</ArticleId><ArticleId IdType="pubmed">36988252</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo B.Q., Li H.B., Yang L.Q. Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12–17 years. Vaccine. 2023;41:4067–4080. doi: 10.1016/j.vaccine.2023.05.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.05.049</ArticleId><ArticleId IdType="pmc">PMC10201323</ArticleId><ArticleId IdType="pubmed">37246067</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidecker B., Dagan N., Balicer R., Eriksson U., Rosano G., Coats A., Tschope C., Kelle S., Poland G.A., Frustaci A., et al. Myocarditis following COVID-19 vaccine: Incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. Eur. J. Heart Fail. 2022;24:2000–2018. doi: 10.1002/ejhf.2669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2669</ArticleId><ArticleId IdType="pmc">PMC9538893</ArticleId><ArticleId IdType="pubmed">36065751</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Chen Y.X., Zhao Y., Lung D.C., Ye Z.H., Song W.C., Liu F.F., Cai J.P., Wong W.M., Yip C.C.Y., et al. Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model (vol 73, pg 2372, 2021) Clin. Infect. Dis. 2021;73:2372–2373. doi: 10.1093/cid/ciab941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab941</ArticleId><ArticleId IdType="pmc">PMC8436386</ArticleId><ArticleId IdType="pubmed">34406358</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela P.L., Simpson R.J., Castillo-Garcia A., Lucia A. Physical activity: A coadjuvant treatment to COVID-19 vaccination? Brain Behav. Immun. 2021;94:1–3. doi: 10.1016/j.bbi.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.03.003</ArticleId><ArticleId IdType="pmc">PMC7937336</ArticleId><ArticleId IdType="pubmed">33691149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghram A., Moalla W., Lavie C.J. Vaccine and physical activity in the era of COVID-19 pandemic. Prog. Cardiovasc. Dis. 2021;67:33–34. doi: 10.1016/j.pcad.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7952126</ArticleId><ArticleId IdType="pubmed">33716015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallam J., Jones T., Alley J., Kohut M.L. Exercise after influenza or COVID-19 vaccination increases serum antibody without an increase in side effects. Brain Behav. Immun. 2022;102:1–10. doi: 10.1016/j.bbi.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8816799</ArticleId><ArticleId IdType="pubmed">35131444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabinian A.E., Kiel R.J., Smith F., Ho K.L., Khatib R., Reyes M.P. Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model. J. Lab. Clin. Med. 1990;115:454–462.</Citation><ArticleIdList><ArticleId IdType="pubmed">2157783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilback N.G., Fohlman J., Friman G. Exercise in coxsackie B3 myocarditis: Effects on heart lymphocyte subpopulations and the inflammatory reaction. Am. Heart J. 1989;117:1298–1302. doi: 10.1016/0002-8703(89)90409-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-8703(89)90409-2</ArticleId><ArticleId IdType="pubmed">2543197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiel R.J., Smith F.E., Chason J., Khatib R., Reyes M.P. Coxsackievirus B3 myocarditis in C3H/HeJ mice: Description of an inbred model and the effect of exercise on virulence. Eur. J. Epidemiol. 1989;5:348–350. doi: 10.1007/BF00144836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00144836</ArticleId><ArticleId IdType="pubmed">2551723</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatmaitan B.G., Chason J.L., Lerner A.M. Augmentation of the virulence of murine coxsackie-virus B-3 myocardiopathy by exercise. J. Exp. Med. 1970;131:1121–1136. doi: 10.1084/jem.131.6.1121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.131.6.1121</ArticleId><ArticleId IdType="pmc">PMC2138852</ArticleId><ArticleId IdType="pubmed">4246139</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilles J.G., Elson S.H., Shaka J.A., Abelmann W.H., Lerner A.M., Finland M. Effects of Exercise on Coxsackie A9 Myocarditis in Adult Mice. Proc. Soc. Exp. Biol. Med. 1964;117:777. doi: 10.3181/00379727-117-29696.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-117-29696</ArticleId><ArticleId IdType="pubmed">14244953</ArticleId></ArticleIdList></Reference><Reference><Citation>Favere K., Van Hecke M., Eens S., Bosman M., Delputte P.L., De Sutter J., Fransen E., Roskams T., Guns P.J., Heidbuchel H. The influence of endurance exercise training on myocardial fibrosis and arrhythmogenesis in a coxsackievirus B3 myocarditis mouse model. Sci. Rep. 2024;14:12653. doi: 10.1038/s41598-024-61874-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-61874-x</ArticleId><ArticleId IdType="pmc">PMC11144711</ArticleId><ArticleId IdType="pubmed">38825590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia A., Solberg E.E., Papadakis M., Adami P.E., Biffi A., Caselli S., La Gerche A., Niebauer J., Pressler A., Schmied C.M., et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: Position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC) Eur. Heart J. 2019;40:19–33. doi: 10.1093/eurheartj/ehy730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy730</ArticleId><ArticleId IdType="pubmed">30561613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosman M., Favere K., Neutel C.H.G., Jacobs G., De Meyer G.R.Y., Martinet W., Van Craenenbroeck E.M., Guns P.D.F. Doxorubicin induces arterial stiffness: A comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice. Toxicol. Lett. 2021;346:23–33. doi: 10.1016/j.toxlet.2021.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2021.04.015</ArticleId><ArticleId IdType="pubmed">33895255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankhead P., Loughrey M.B., Fernandez J.A., Dombrowski Y., McArt D.G., Dunne P.D., McQuaid S., Gray R.T., Murray L.J., Coleman H.G., et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 2017;7:16878. doi: 10.1038/s41598-017-17204-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17204-5</ArticleId><ArticleId IdType="pmc">PMC5715110</ArticleId><ArticleId IdType="pubmed">29203879</ArticleId></ArticleIdList></Reference><Reference><Citation>Geens J.H., Jacobs S., Claus P., Trenson S., Leunens V., Vantichelen I., Rega F.R., Verbeken E.K., Burkhoff D., Meyns B. Partial mechanical circulatory support in an ovine model of post-infarction remodeling. J. Heart Lung Transplant. 2013;32:815–822. doi: 10.1016/j.healun.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2013.05.019</ArticleId><ArticleId IdType="pubmed">23856219</ArticleId></ArticleIdList></Reference><Reference><Citation>Eens S., Van Hecke M., Favere K., Tousseyn T., Guns P.J., Roskams T., Heidbuchel H. B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: A case report. Front. Oncol. 2023;13:1158124. doi: 10.3389/fonc.2023.1158124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2023.1158124</ArticleId><ArticleId IdType="pmc">PMC10183601</ArticleId><ArticleId IdType="pubmed">37197431</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M., Mei X.W., Handunnetthi L., Dixon S., Zaccardi F., Shankar-Hari M., Watkinson P., Khunti K., Harnden A., Coupland C.A.C., et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022;146:743–754. doi: 10.1161/CIRCULATIONAHA.122.059970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.059970</ArticleId><ArticleId IdType="pmc">PMC9439633</ArticleId><ArticleId IdType="pubmed">35993236</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee for Medicinal Products for Human Use . Assessment Report EMA. European Medicines Agency; Amsterdan, The Netherlands: 2012. CHMP/709596/2012.</Citation></Reference><Reference><Citation>European Medicines Agency . Comirnaty COVID-19 mRNA Vaccine (Nucleoside-Modified) EMA; Amsterdan, The Netherlands: 2021.</Citation></Reference><Reference><Citation>Bril F., Al Diffalha S., Dean M., Fettig D.M. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J. Hepatol. 2021;75:222–224. doi: 10.1016/j.jhep.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8056822</ArticleId><ArticleId IdType="pubmed">33862041</ArticleId></ArticleIdList></Reference><Reference><Citation>Shroff H., Satapathy S.K., Crawford J.M., Todd N.J., VanWagner L.B. Liver injury following SARS-CoV-2 vaccination: A multicenter case series. J. Hepatol. 2022;76:211–214. doi: 10.1016/j.jhep.2021.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.07.024</ArticleId><ArticleId IdType="pmc">PMC8324396</ArticleId><ArticleId IdType="pubmed">34339763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Yuen T.T.-T., Dou Y., Hu J., Li R., Zeng Z., Lin X., Gong H., Chan C.H.-C., Yoon C., et al. Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response. Nat. Commun. 2023;14:3440. doi: 10.1038/s41467-023-39096-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39096-y</ArticleId><ArticleId IdType="pmc">PMC10257169</ArticleId><ArticleId IdType="pubmed">37301910</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Lee A., Grigoryan L., Arunachalam P.S., Scott M.K.D., Trisal M., Wimmers F., Sanyal M., Weidenbacher P.A., Feng Y., et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 2022;23:543–555. doi: 10.1038/s41590-022-01163-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01163-9</ArticleId><ArticleId IdType="pmc">PMC8989677</ArticleId><ArticleId IdType="pubmed">35288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., Edwards D.K., Leist S.R., Abiona O.M., Boyoglu-Barnum S., Gillespie R.A., Himansu S., Schäfer A., Ziwawo C.T., DiPiazza A.T., et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571. doi: 10.1038/s41586-020-2622-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2622-0</ArticleId><ArticleId IdType="pmc">PMC7581537</ArticleId><ArticleId IdType="pubmed">32756549</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman E., Eldridge S. Spontaneously occurring cardiovascular lesions in commonly used laboratory animals. Cardiooncology. 2019;5:6. doi: 10.1186/s40959-019-0040-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40959-019-0040-y</ArticleId><ArticleId IdType="pmc">PMC7048038</ArticleId><ArticleId IdType="pubmed">32154013</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass A.M., Coombs W., Taffet S.M. Spontaneous cardiac calcinosis in BALB/cByJ mice. Comp. Med. 2013;63:29–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567374</ArticleId><ArticleId IdType="pubmed">23561935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini O., Casazza A.M., di Marco A. Histological and histochemical studies of myocardial lesions in BALBc/Cr mice. Lab. Anim. Sci. 1976;26:329–333.</Citation><ArticleIdList><ArticleId IdType="pubmed">1271745</ArticleId></ArticleIdList></Reference><Reference><Citation>Potere N., Del Buono M.G., Caricchio R., Cremer P.C., Vecchie A., Porreca E., Dalla Gasperina D., Dentali F., Abbate A., Bonaventura A. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications. EBioMedicine. 2022;85:104299. doi: 10.1016/j.ebiom.2022.104299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104299</ArticleId><ArticleId IdType="pmc">PMC9536001</ArticleId><ArticleId IdType="pubmed">36209522</ArticleId></ArticleIdList></Reference><Reference><Citation>Declercq J., De Leeuw E., Lambrecht B.N. Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: From prognostic marker to therapeutic agent. Cytokine. 2022;157:155934. doi: 10.1016/j.cyto.2022.155934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2022.155934</ArticleId><ArticleId IdType="pmc">PMC9170572</ArticleId><ArticleId IdType="pubmed">35709568</ArticleId></ArticleIdList></Reference><Reference><Citation>Todorović-Raković N., Whitfield J.R. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease. Cytokine. 2021;146:155637. doi: 10.1016/j.cyto.2021.155637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155637</ArticleId><ArticleId IdType="pmc">PMC8253693</ArticleId><ArticleId IdType="pubmed">34242899</ArticleId></ArticleIdList></Reference><Reference><Citation>Levick S.P., Goldspink P.H. Could interferon-gamma be a therapeutic target for treating heart failure? Heart Fail Rev. 2014;19:227–236. doi: 10.1007/s10741-013-9393-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-013-9393-8</ArticleId><ArticleId IdType="pmc">PMC3844057</ArticleId><ArticleId IdType="pubmed">23589353</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D., Hammi I., Kihel A., El Idrissi Saik I., Guessous F., Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb. Pathog. 2021;153:104799. doi: 10.1016/j.micpath.2021.104799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104799</ArticleId><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V., Kaur R., Kumari P., Pasricha C., Singh R. ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders. Clin. Chim. Acta. 2023;548:117487. doi: 10.1016/j.cca.2023.117487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2023.117487</ArticleId><ArticleId IdType="pubmed">37442359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap R.X.L., Lai Y.W., Wei C., Ng J.J.W., Xu D., Feng S., Mu R., Thong B.Y.-H., Xu C. Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases. Vaccines. 2024;12:274. doi: 10.3390/vaccines12030274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030274</ArticleId><ArticleId IdType="pmc">PMC10974321</ArticleId><ArticleId IdType="pubmed">38543908</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino R., Pellino G., Selvaggi L., Selvaggi F., Federico A., Romano M., Gravina A.G. BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: A monocentric real-life study. Expert Rev. Clin. Pharmacol. 2022;15:1243–1252. doi: 10.1080/17512433.2022.2120466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2022.2120466</ArticleId><ArticleId IdType="pubmed">36047032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettini E., Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines. 2021;9:147. doi: 10.3390/vaccines9020147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020147</ArticleId><ArticleId IdType="pmc">PMC7918810</ArticleId><ArticleId IdType="pubmed">33673048</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchant H. Inadvertent injection of COVID-19 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions. Postgrad. Med. J. 2022;98:e5. doi: 10.1136/postgradmedj-2021-141119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-141119</ArticleId><ArticleId IdType="pubmed">37066510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocker M.S., Abdel-Aty H., Strohm O., Friedrich M.G. Age and gender effects on the extent of myocardial involvement in acute myocarditis: A cardiovascular magnetic resonance study. Heart. 2009;95:1925–1930. doi: 10.1136/hrt.2008.164061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.2008.164061</ArticleId><ArticleId IdType="pubmed">19710029</ArticleId></ArticleIdList></Reference><Reference><Citation>Potluri T., Fink A.L., Sylvia K.E., Dhakal S., Vermillion M.S., vom Steeg L., Deshpande S., Narasimhan H., Klein S.L. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. npj Vaccines. 2019;4:29. doi: 10.1038/s41541-019-0124-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-019-0124-6</ArticleId><ArticleId IdType="pmc">PMC6626024</ArticleId><ArticleId IdType="pubmed">31312529</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguiar A.S., Jr., Speck A.E., Amaral I.M., Canas P.M., Cunha R.A. The exercise sex gap and the impact of the estrous cycle on exercise performance in mice. Sci. Rep. 2018;8:10742. doi: 10.1038/s41598-018-29050-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-29050-0</ArticleId><ArticleId IdType="pmc">PMC6048134</ArticleId><ArticleId IdType="pubmed">30013130</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S.L., Flanagan K.L. Sex differences in immune responses. Nat. Rev. Immunol. 2016;16:626–638. doi: 10.1038/nri.2016.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzych U., Strausser H.R., Bressler J.P., Goldstein A.L. Quantitative differences in immune responses during the various stages of the estrous cycle in female BALB/c mice. J. Immunol. 1978;121:1603–1605. doi: 10.4049/jimmunol.121.4.1603.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.121.4.1603</ArticleId><ArticleId IdType="pubmed">308972</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X., Zaks T., Langer R., Dong Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021;6:1078–1094. doi: 10.1038/s41578-021-00358-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00358-0</ArticleId><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker L.M., Swank Z., Bartsch Y.C., Burns M.D., Kane A., Boribong B.P., Davis J.P., Loiselle M., Novak T., Senussi Y., et al. Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis. Circulation. 2023;147:867–876. doi: 10.1161/CIRCULATIONAHA.122.061025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.061025</ArticleId><ArticleId IdType="pmc">PMC10010667</ArticleId><ArticleId IdType="pubmed">36597886</ArticleId></ArticleIdList></Reference><Reference><Citation>Forte E. Circulating spike protein may contribute to myocarditis after COVID-19 vaccination. Nat. Cardiovasc. Res. 2023;2:100. doi: 10.1038/s44161-023-00222-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44161-023-00222-0</ArticleId><ArticleId IdType="pubmed">39196056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L., Deng W., Huang B., Gao H., Liu J., Ren L., Wei Q., Yu P., Xu Y., Qi F., et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583:830–833. doi: 10.1038/s41586-020-2312-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2312-y</ArticleId><ArticleId IdType="pubmed">32380511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S.H., Chen Q., Gu H.J., Yang G., Wang Y.X., Huang X.Y., Liu S.S., Zhang N.N., Li X.F., Xiong R., et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe. 2020;28:124–133.e124. doi: 10.1016/j.chom.2020.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.05.020</ArticleId><ArticleId IdType="pmc">PMC7250783</ArticleId><ArticleId IdType="pubmed">32485164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Zhuang Z., Zheng J., Li K., Wong R.L., Liu D., Huang J., He J., Zhu A., Zhao J., et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. 2020;182:734–743.e735. doi: 10.1016/j.cell.2020.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.010</ArticleId><ArticleId IdType="pmc">PMC7284240</ArticleId><ArticleId IdType="pubmed">32643603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>